KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Notes Payables (2016 - 2026)

Bio-Rad Laboratories has reported Notes Payables over the past 18 years, most recently at $400.5 million for Q1 2026.

  • Quarterly Notes Payables rose 33275.0% to $400.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $400.5 million through Mar 2026, up 33275.0% year-over-year, with the annual reading at $1.3 million for FY2025, 8.33% up from the prior year.
  • Notes Payables was $400.5 million for Q1 2026 at Bio-Rad Laboratories, up from $1.3 million in the prior quarter.
  • Over five years, Notes Payables peaked at $400.5 million in Q1 2026 and troughed at $448000.0 in Q3 2022.
  • The 5-year median for Notes Payables is $504000.0 (2022), against an average of $24.3 million.
  • Year-over-year, Notes Payables tumbled 74.24% in 2022 and then skyrocketed 33275.0% in 2026.
  • A 5-year view of Notes Payables shows it stood at $465000.0 in 2022, then rose by 7.53% to $500000.0 in 2023, then soared by 140.0% to $1.2 million in 2024, then increased by 8.33% to $1.3 million in 2025, then soared by 30707.69% to $400.5 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Notes Payables are $400.5 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025).